Indication
Corneal Endothelial Cell Loss
1 clinical trial
3 products
Product
Vehicle OphthalmicProduct
OmaveloxoloneClinical trial
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract SurgeryStatus: Completed, Estimated PCD: 2015-02-28
Product
Vehicle Ophthalmic Solution